Dicerna Pharmaceuticals, An RNA Interference Company, To Present at Discovery on Target Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics in multiple disease areas, today announced that Bob D. Brown, Ph.D., senior vice president of research, Dicerna, and Dicerna co-founder and Scientific Advisory Board member Mark Behlke, M.D., Ph.D., vice president of molecular genetics and biophysics and chief scientific officer at Integrated DNA Technologies (IDT), will present at the Discovery on Target Conference at the World Trade Center in Boston, Mass. The conference will be held October 20-23, 2008, and is broken up into several sub-conferences. Dicerna will lead sessions at two of these sub-conferences, including the 6th Annual RNAi for Screening Conference, as well as the 2nd Annual RNAi for Therapeutics Conference.